Overview Dividends

(EXAS) EXACT Sciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30063P1057

Colorectal, Breast, Colon, Hereditary, Tumor, Monitoring

EXAS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 277.58%
EPS Trend (3Y Correlation): 66.3%

EXAS Revenue

Revenue Growth (3Y CAGR): 16.96%
Revenue Trend (3Y Correlation): 95.7%

Risk via 10d forecast
Volatility	47.7%
Value at Risk 5%th	70.2%
Relative Tail Risk	-10.40%

Reward TTM
Sharpe Ratio	0.77
Alpha	20.56

Character TTM
Hurst Exponent	0.427
Beta	0.911
Beta Downside	0.584

Drawdowns 3y
Max DD	59.30%
Mean DD	32.21%
Median DD	36.65%

Description: EXAS EXACT Sciences November 03, 2025

Exact Sciences Corp. (NASDAQ:EXAS) develops and commercializes non-invasive cancer screening and diagnostic tests, most notably Cologuard-a stool-based DNA and hemoglobin assay approved for colorectal cancer (CRC) detection and widely adopted in the U.S. screening pathway.

Beyond Cologuard, the firm offers a suite of genomic-based diagnostics, including the Oncotype DX series for breast, DCIS, and colon recurrence risk, the OncoExTra tumor-profiling panel for advanced cancers, and the RiskGuard hereditary cancer test. These products target high-margin, payer-reimbursed niches within oncology diagnostics.

Exact’s pipeline aims to expand into earlier-stage risk assessment, neoadjuvant treatment selection, and recurrence monitoring, leveraging partnerships with the Mayo Foundation and Johns Hopkins University to accelerate validation and market entry. The company’s pipeline breadth reduces reliance on any single product line, a key risk mitigant for investors.

Key metrics: FY 2023 revenue reached approximately $1.5 billion, driven by a ~15 % year-over-year increase in Cologuard sales, and the test now commands roughly 70 % of the U.S. stool-DNA market. The firm holds over $2 billion in cash and short-term investments, providing runway for pipeline development and potential acquisitions. Sector-wide, the aging U.S. population and expanding Medicare coverage for CRC screening underpin a multi-year growth tail for Exact’s core offerings.

For a deeper quantitative assessment, you may find the ValueRay platform’s EXAS valuation model a useful next step.

EXAS Stock Overview

Market Cap in USD	12,539m
Sub-Industry	Biotechnology
IPO / Inception	2001-02-01
Return 12m vs S&P 500	14.8%
Analyst Rating	4.54 of 5

EXAS Dividends

Currently no dividends paid

EXAS Growth Ratios

CAGR 3y	16.54%
CAGR/Max DD Calmar Ratio	0.28
CAGR/Mean DD Pain Ratio	0.51
Current Volume	1734.8k
Average Volume	2424.6k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-986.6m TTM) > 0 and > 6% of Revenue (6% = 184.9m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 32.66% (prev 30.07%; Δ 2.59pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 386.8m > Net Income -986.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (189.3m) change vs 12m ago 2.42% (target <= -2.0% for YES)

Gross Margin 67.36% (prev 72.10%; Δ -4.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 48.73% (prev 39.89%; Δ 8.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -25.24 (EBITDA TTM -870.4m / Interest Expense TTM 38.4m) >= 6 (WARN >= 3)

Altman Z'' -3.89

(A) 0.17 = (Total Current Assets 1.59b - Total Current Liabilities 584.3m) / Total Assets 5.90b

(B) -0.78 = Retained Earnings (Balance) -4.62b / Total Assets 5.90b

(D) -1.36 = Book Value of Equity -4.61b / Total Liabilities 3.40b

Total Rating: -3.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.38

1. Piotroski 3.50pt = -1.50

2. FCF Yield 1.76% = 0.88

3. FCF Margin 8.02% = 2.00

4. Debt/Equity 1.01 = 2.01

5. Debt/Ebitda -2.01 = -2.50

6. ROIC - WACC (= -26.20)% = -12.50

7. RoE -40.39% = -2.50

8. Rev. Trend 95.67% = 7.18

9. EPS Trend 66.32% = 3.32

What is the price of EXAS shares?

As of November 16, 2025, the stock is trading at USD 67.03 with a total of 1,734,834 shares traded.
Over the past week, the price has changed by +1.28%, over one month by +10.68%, over three months by +48.99% and over the past year by +31.61%.

Is EXACT Sciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, EXACT Sciences (NASDAQ:EXAS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 46.38 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXAS is around 62.91 USD . This means that EXAS is currently overvalued and has a potential downside of -6.15%.

Is EXAS a buy, sell or hold?

EXACT Sciences has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy EXAS.

Strong Buy: 17
Buy: 6
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EXAS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	80.2	19.6%
Analysts Target Price	80.2	19.6%
ValueRay Target Price	69.7	4%

EXAS Fundamental Data Overview November 10, 2025

Market Cap USD = 12.54b (12.54b USD * 1.0 USD.USD)
P/E Forward = 90.9091
P/S = 4.0685
P/B = 4.3078
P/EG = -1.07
Beta = 1.472
Revenue TTM = 3.08b USD
EBIT TTM = -968.7m USD
EBITDA TTM = -870.4m USD
Long Term Debt = 2.32b USD (from longTermDebt, last fiscal year)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.75b USD (from netDebt column, last quarter)
Enterprise Value = 14.07b USD (12.54b + Debt 2.54b - CCE 1.00b)
Interest Coverage Ratio = -25.24 (Ebit TTM -968.7m / Interest Expense TTM 38.4m)
FCF Yield = 1.76% (FCF TTM 247.1m / Enterprise Value 14.07b)
FCF Margin = 8.02% (FCF TTM 247.1m / Revenue TTM 3.08b)
Net Margin = -32.01% (Net Income TTM -986.6m / Revenue TTM 3.08b)
Gross Margin = 67.36% ((Revenue TTM 3.08b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 68.64% (prev 69.35%)
Tobins Q-Ratio = 2.38 (Enterprise Value 14.07b / Total Assets 5.90b)
Interest Expense / Debt = 0.39% (Interest Expense 9.79m / Debt 2.54b)
Taxrate = 8.57% (-1.84m / -21.4m)
NOPAT = -885.6m (EBIT -968.7m * (1 - 8.57%)) [loss with tax shield]
Current Ratio = 2.72 (Total Current Assets 1.59b / Total Current Liabilities 584.3m)
Debt / Equity = 1.01 (Debt 2.54b / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = -2.01 (negative EBITDA) (Net Debt 1.75b / EBITDA -870.4m)
Debt / FCF = 7.07 (Net Debt 1.75b / FCF TTM 247.1m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.72% (Net Income -986.6m / Total Assets 5.90b)
RoE = -40.39% (Net Income TTM -986.6m / Total Stockholder Equity 2.44b)
RoCE = -20.33% (EBIT -968.7m / Capital Employed (Equity 2.44b + L.T.Debt 2.32b))
RoIC = -18.34% (negative operating profit) (NOPAT -885.6m / Invested Capital 4.83b)
WACC = 7.85% (E(12.54b)/V(15.07b) * Re(9.37%) + D(2.54b)/V(15.07b) * Rd(0.39%) * (1-Tc(0.09)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.22%
[DCF Debug] Terminal Value 64.70% ; FCFE base≈187.6m ; Y1≈123.2m ; Y5≈56.3m
Fair Price DCF = 4.75 (DCF Value 899.7m / Shares Outstanding 189.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 66.32 | EPS CAGR: 277.6% | SUE: 1.38 | # QB: 1
Revenue Correlation: 95.67 | Revenue CAGR: 16.96% | SUE: 3.21 | # QB: 3

Additional Sources for EXAS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle